# OnCo record xilio-therapeutics (company). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)". Whole corpus: https://onco.cc/api/v1/onco.nt
@prefix schema: <https://schema.org/> .
@prefix onco: <https://onco.cc/ns#> .
@prefix xsd: <http://www.w3.org/2001/XMLSchema#> .

<https://onco.cc/companies/xilio-therapeutics/>
  a schema:Organization ;
  onco:kind "company" ;
  schema:identifier "xilio-therapeutics" ;
  schema:name "Xilio Therapeutics"@en ;
  schema:description "Xilio designs immune-stimulating drugs, such as interleukin-2 and checkpoint antibodies, with a molecular mask that is removed only inside tumours, so they act where the cancer is and spare the rest of the body. Its newest drug combines a PD-1 antibody with masked IL-2 and has just been cleared to start trials."@en ;
  schema:url <https://onco.cc/companies/xilio-therapeutics/>, <https://xiliotx.com/> ;
  schema:dateModified "2026-09-10"^^xsd:date ;
  schema:citation <https://xiliotx.com/>, <https://www.sec.gov/Archives/edgar/data/1840233/000119312526345753/xlo-ex99_1.htm> ;
  schema:addressCountry "US" ;
  onco:cancers <https://onco.cc/cancers/nsclc/> ;
  onco:sections <https://onco.cc/fronts/immunotherapy/> ;
  onco:technologies <https://onco.cc/technologies/cytokine-therapy/>, <https://onco.cc/technologies/checkpoint-inhibitor/>, <https://onco.cc/technologies/bispecific-antibody/>, <https://onco.cc/technologies/t-cell-engager/> ;
  onco:targets <https://onco.cc/targets/pd1/>, <https://onco.cc/targets/ctla4/>, <https://onco.cc/targets/cldn18-2/>, <https://onco.cc/targets/psma/> ;
  onco:trials <https://onco.cc/trials/nct05684965/> .